Booster Confusion

For the 15 million Americans who have received the Johnson & Johnson Covid vaccine, the confusing messages from the federal government just keep coming.

An F.D.A. advisory panel is scheduled to vote today on whether J. & J. recipients should receive a booster shot. But the panel is not likely to vote on what seems to be the most relevant question: Should the booster shot come from one of the other vaccines — Pfizer’s or Moderna’s, which are known as mRNA vaccines — rather than a follow-up J. & J. shot?

The scientific evidence increasingly suggests that the answer is yes (as I explain below). Still, the F.D.A. panel seems likely to duck the question and rule only on whether J. & J. recipients should receive a J. & J. booster.

It is the latest example of a recurring Covid problem. Again and again, government officials have chosen to follow pre-existing bureaucratic procedures even when doing so has led to widespread public confusion and counterproductive behavior.

Officials often defend this approach by saying they merely “follow the science,” but that’s not quite accurate. When there is a conflict between scientific evidence and bureaucratic protocols, science often takes a back seat. Consider:

• At the start of the pandemic, health officials around the country were desperate to conduct Covid-19 tests, but the C.D.C. sometimes kept those officials from developing their own tests — even as the C.D.C.’s own initial test was a failure.

• Around the same time, federal officials discouraged the public from wearing masks, saying there was not enough evidence to support them — despite masks’ longtime effectiveness in Asia and inside hospitals.

• For much of this year, the F.D.A. refused to grant full authorization to any Covid vaccine — even as its top leaders were saying the shots were safe and effective and urging Americans to get vaccinated.

• The F.D.A. has been slow to approve rapid Covid tests, which helps explain why Britain, France and Germany are awash in the tests — but your local drugstore may not have any.

The repeated slowness of U.S. officials stems from a worthy goal. They want to consider the scientific evidence carefully before making decisions. They want to avoid confusing the public or, even worse, promoting less than optimal medical treatments.

Yet in their insistence on following procedures that were not written with a global pandemic in mind, officials have often ended up doing precisely what they sought to avoid. They have perplexed the public and encouraged medically dubious behavior.

During a public-health crisis, officials are most effective when they are “first, right and credible,” as the sociologist and Times Opinion columnist Zeynep Tufekci has written. They are least effective when they offer “mixed messaging, delays and confusion.”

The J. & J. question

Last month, this newsletter published a guide to whether J. & J. recipients should follow the mix-and-match approach of getting a booster shot with the Pfizer or Moderna vaccine. We concluded that the available scientific evidence argued for the mix-and-match approach, but that there was still uncertainty. We wrote that we understood why many people would not want to do so until the government encouraged it.

This week, the data in favor of the mix-and-match approach became even stronger.

The National Institutes of Health, which is part of the federal government, released a study comparing the antibody levels in J. & J. recipients who had received a J. & J. booster with those who had received an mRNA booster. With both of the mRNA shots — Moderna’s and Pfizer’s — the antibody levels were higher. The study did not involve enough people or a long enough time frame to be definitive, but many experts believe it’s significant.

It also follows other evidence in favor of a mix-and-match approach. In other countries, a similar approach appears to be successful. Partly as a result, an unknown number of U.S. doctors and scientists who received the J. & J. vaccine have already taken it upon themselves to get a follow-up shot from Pfizer or Moderna. And the city of San Francisco already offers mix-and-match booster shots. “At the end of the day, folks having the Johnson & Johnson should probably get an mRNA booster,” Scott Hensley, an immunologist at the University of Pennsylvania, told The Times.

Absent a late addition to its agenda, however, the F.D.A. panel will only discuss the mix-and-match issue today but take no action on it. If you’re a J. & J. recipient looking for clarity from your government, you’re on your own.

A National Health Adviser?

Bureaucratic sluggishness and confusion are not new problems. At several points in U.S. history, the federal government has taken steps to address them.

In 1947, Congress created the National Security Council to help the president make sense of competing advice from military leaders, diplomats and others. In the 1990s, Bill Clinton created a similar council to coordinate economic policy. And some individual officials — like Ben Bernanke, the former Federal Reserve chairman — previously managed to avoid the problem that has bedeviled the F.D.A. and C.D.C.: These officials refused to let inertia block common-sense policies during a crisis. Bernanke’s memoir, as I’ve noted before, is titled “The Courage to Act.”

During the pandemic, many Americans have come to think of Dr. Anthony Fauci as playing a similar role. He occasionally has (especially when Donald Trump was flouting medical evidence). But Fauci is an N.I.H. official who lacks the power to coordinate federal policy. It isn’t his job to clarify the government’s competing public-health messages. He has not done so on some big issues, including rapid tests and J. & J. boosters.

Nobody has. As a result, federal policy has sometimes fallen behind the scientific evidence, leaving many Americans to feel confused and frustrated — and the country’s Covid response to be less effective than it could have been.

More on the virus:

• An F.D.A. panel recommended booster shots for high-risk Moderna recipients.

• “As winter looms, there are real reasons for optimism,” The Times’s Emily Anthes writes about the state of the pandemic in the U.S.

THE LATEST NEWS

International

• At least six people died in Beirut during protests related to last year’s huge blast at the city’s port.

• LinkedIn, the last major U.S. social network in China, is shutting down there.

Politics

• The committee investigating the Capitol riot is planning to recommend criminal charges against Steve Bannon for defying a congressional subpoena.

• The Justice Department reversed the firing of Andrew McCabe, the former deputy F.B.I. director Trump routinely criticized.

Other Big Stories

• The frenzied housing market is prompting rent increases.

• The South Carolina lawyer Alex Murdaugh was charged with swindling millions from the sons of his former housekeeper.

• A comedy special by Dave Chappelle, criticized as transphobic, has prompted an uproar at Netflix.

• Robert Durst, the subject of the documentary “The Jinx,” was sentenced to life in prison for the 2000 murder of a friend.

• Emails show the cozy relationship between Jeff Pash, the N.F.L.’s top lawyer, and the former president of the Washington Football Team.

Opinions

Horror movies, novels and TV shows reflect our anxieties. They also offer solace, Stephen Graham Jones argues.

The Supreme Court may now belong to Clarence Thomas, says Jill Abramson.

Nicholas Kristof, the Pulitzer-winning columnist, is leaving The Times as he weighs a run for governor of Oregon.

MORNING READS

Scam or not: Do stress-relieving drinks work?

Collectibles: The fight for sneakers.

Modern Love: A missing sock can change your life.

Advice from Wirecutter: These smokeless fire pits and patio heaters are perfect for fall.

Lives Lived: Russ Kick, a self-described “rogue transparency activist,” used the Freedom of Information Act to exquisite effect, exposing documents that sometimes made front-page news. He died at 52.

Gary Paulsen’s young-adult novels, including “Hatchet” and “Dogsong,” inspired generations with their tales of exploration. Paulsen died at 82.

ARTS AND IDEAS

When wealth looks bleak

The new season of the HBO drama “Succession,” which chronicles the dysfunction of a family of media billionaires, begins on Sunday. Though the show shares DNA with dramas like “Dynasty” and “Dallas” that also documented the lives of the ultrarich, “Succession” is different, the Times critic James Poniewozik writes.

Its premise is familiar — the show follows siblings who plot to either become the favorite of their father, a mogul, or engineer his downfall. But the show’s depiction of wealth is a departure from its predecessors. In ’80s TV soaps, being rich looked glamorous and offered escapism. The opening sequence of the original “Dynasty,” for example, featured Joan Collins “wearing bejeweled earrings the size of squash racquets,” Poniewozik writes.

On “Succession,” being rich seems much less fun. The aesthetic of the show is cold: Opening episodes of the new season take place in conference rooms, on tarmacs, inside airplanes and cars. Even the parties the characters attend “look like conceptual art installations and feel like work,” Poniewozik writes.

“Succession” remains a cult favorite rather than a huge hit, and its central family’s untouchability may be one reason. What attracts viewers is the drama, however bleak. “The good guys are not even in the game,” Poniewozik writes. “You can only hope to see a terrible person do something terrible to a more terrible person.” — Sanam Yar, a Morning writer

PLAY, WATCH, EAT

What to Cook

Studded with salty olives, pancetta and Parmesan, this is not your average roasted cauliflower.

What to Watch

Looking for the perfect slice-of-life comedy? Catch up on “Insecure” before the show’s final season.

Late Night

The hosts joked about Trump.

Take the News Quiz

Test your knowledge of this week’s headlines.

Now Time to Play

The pangrams from yesterday’s Spelling Bee were extenuated and untaxed. Here is today’s puzzle — or you can play online.

Here’s today’s Mini Crossword, and a clue: Chef’s wear (five letters).

If you’re in the mood to play more, find all our games here.

Thanks for spending part of your morning with The Times. See you Monday. — David

P.S. Mujib Mashal will become The Times’s South Asia bureau chief.

Here’s today’s print front page.

“The Daily” is about delays and rising costs of goods.

Claire Moses, Ian Prasad Philbrick, Ashley Wu and Sanam Yar contributed to The Morning. You can reach the team at [email protected].

Sign up here to get this newsletter in your inbox.